Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Free Cash Flow (2021 - 2025)

Historic Free Cash Flow for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to -$9.8 million.

  • Kezar Life Sciences' Free Cash Flow rose 4386.71% to -$9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$56.7 million, marking a year-over-year increase of 2582.54%. This contributed to the annual value of -$74.2 million for FY2024, which is 1104.07% up from last year.
  • As of Q3 2025, Kezar Life Sciences' Free Cash Flow stood at -$9.8 million, which was up 4386.71% from -$12.8 million recorded in Q2 2025.
  • Kezar Life Sciences' 5-year Free Cash Flow high stood at -$8.4 million for Q1 2021, and its period low was -$22.9 million during Q1 2024.
  • Its 5-year average for Free Cash Flow is -$15.8 million, with a median of -$16.8 million in 2024.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 6781.76% in 2022, then soared by 4386.71% in 2025.
  • Kezar Life Sciences' Free Cash Flow (Quarter) stood at -$11.3 million in 2021, then plummeted by 43.02% to -$16.2 million in 2022, then fell by 16.98% to -$19.0 million in 2023, then grew by 11.3% to -$16.8 million in 2024, then soared by 41.61% to -$9.8 million in 2025.
  • Its Free Cash Flow stands at -$9.8 million for Q3 2025, versus -$12.8 million for Q2 2025 and -$17.2 million for Q1 2025.